| quinupristin-dalfopristin-resistant enterococcus faecium on chicken and in human stool specimens. | the combination of the streptogramins quinupristin and dalfopristin was approved in the united states in late 1999 for the treatment of vancomycin-resistant enterococcus faecium infections. since 1974, another streptogramin, virginiamycin, has been used at subtherapeutic concentrations to promote the growth of farm animals, including chickens. | 2001 | 11642231 |
| implications of multiple antimicrobial-resistant enterococci associated with the poultry environment. | poultry are increasingly being associated with carriage of multiresistant organisms that may cause disease in humans. among these organisms are the enterococci, not regarded as a common cause of hospital-acquired infections. the use of antimicrobials for growth promotion in poultry production envronments may facilitate the dissemination of resistance to enterococcus spp. that have the potential to be clinically significant. to assess descriptively the degree of multiresistant enterococci in the ... | 2001 | 11761123 |
| distribution of streptogramin resistance determinants among enterococcus faecium from a poultry production environment of the usa. | the impact of agricultural use of antimicrobials on the present and future efficacy of therapeutic drugs in human medicine is a growing public concern. quinupristin/dalfopristin has been approved to treat human disease caused by vancomycin-resistant enterococcus faecium and is related to virginiamycin, a streptogramin complex that has long been used in usa agriculture poultry production. | 2004 | 15574480 |